The European Commission published its decision on the Schering-Plough Corporation and Organon BioSciences N.V. acquisition. The concentration concerns human health products and animal health products, where both parties are active. The Commission stated that the concentration gives rise to horizontal overlaps between the activities of Schering-Plough and Organon BS for the manufacture and marketing of vaccines and pharmaceuticals in the animal health sector. There are overlaps in over 40 products markets, in several EEA countries for each product. The decision first examines the definition of the relevant markets for human health and the competitive assessment of the proposed transaction in the human health sector (Section A), and then the relevant market definition for vaccines and pharmaceuticals in the animal health sector and the competitive assessment of the transaction are examined market by market (Section B).
The Commission accepted commitments and let the acquisition go on.
The reason I do not like such decisions is that – although thorough examination of the competitive conditions, etc. is necessary – such decisions are too complex and long for anybody to read. Of course not counting those in the sector and those who hav advised the clients.